Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306

MLA

F. de Braud, et al. “Reply to FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer–subgroup Analysis of Patients with KRAS-Mutated Tumours in the Randomised German AIO Study KRK-0306.” Annals of Oncology, vol. 23, Oct. 2012, pp. 2771–72. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e4d3872f5b2a935b85c52887e1545441&authtype=sso&custid=ns315887.

APA

F. de Braud, Valter Torri, Marina Chiara Garassino, & Filippo Pietrantonio. (2012). Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. Annals of Oncology, 23, 2771–2772.

Chicago

F. de Braud, Valter Torri, Marina Chiara Garassino, and Filippo Pietrantonio. 2012. “Reply to FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer–subgroup Analysis of Patients with KRAS-Mutated Tumours in the Randomised German AIO Study KRK-0306.” Annals of Oncology 23 (October): 2771–72. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e4d3872f5b2a935b85c52887e1545441&authtype=sso&custid=ns315887.